Lexaria Bioscience: Ingesting Versus Inhaling Could Save 60,000 Lives a Year

Technology for healthier drug molecule delivery

“Everybody knows that smoking is not healthy. Thus, our technology delivers drug molecules like cannabinoids or nicotine through ingesting means. Also, the things that you swallow and that could be a pill, it could be a syrup, could be a cup of coffee. Therefore if we are able to help change the consumption habits of even 1 percent of the global marketplace who smoke we could save 60,000 lives a year.” – Chris Bunka, CEO of Lexaria Bioscience.

Lexaria Bioscience Corp. developed and out-licenses its technology named DehydraTECH™ that promotes –
  • Healthier administration methods
  • Lower overall dosing
  • Higher effectiveness of ingestible drugs and other beneficial molecules.

This technology is protected by a robust suite of patents granted or pending worldwide. Thus is proven effective in multiple international studies and quantity of absorption of a range of molecules. DehydraTECH delivery technology offers a workable and healthier alternative. Basically in other delivery methods for substances such as inhalational delivery through smoking.


For more information on Lexaria Bioscience Corp. (NASDAQ: LEXX) please fill out the form below.

Request Investor Info